Institute for Applied Cancer Science

Singular Focus

Committed to advancing a pipeline of effective drugs into the clinic

To transform cancer care and ensure our efforts improve the lives of patients as quickly as possible, we have comogrmitted to very strict criteria to select and prioritize our drug discovery projects. Following a stringent up-front evaluation process, IACS prams are driven forward by cross-functional project teams according to a comprehensive work plan, which includes predefined decision points. These Go/No-Go decision points allow for risk mitigation while the project potential is objectively evaluated, providing definitive exit points if a program is not performing as anticipated. This evaluation process prevents time and resources from being wasted by programs that will not reach the clinic, allowing deployment of resources elsewhere.

 

 

 

 

Three elements are essential for the success of each program in the IACS portfolio:

 

  • Discovery of molecules with the appropriate properties to safely and effectively inhibit the target in patients for the required duration, and that can be combined with other agents;
  • Comprehensive understanding of the biological role of the drug target in initiating and sustaining tumor growth; and in what context
  • Enrollment of appropriate patient subsets into smart clinical trials based on specific characteristics of each patient’s disease.